CD28 and neoplasm: Treatment with anti‐CD3/CD28 increased the frequency of CD137+/CD8+ T cells and induced cytokine responses dominated by IFNγ, IL‐2, and Granzyme B. While both non‐tumor and tumor‐border tissue responded to anti‐CD3/CD28, the intensities of immune responses were highly varied.